Publications by authors named "J Szumowski"
Article Synopsis
- A study at the Ward 86 HIV clinic in San Francisco investigated the effectiveness of long-acting cabotegravir/rilpivirine (LA-CAB/RPV) in rapidly achieving and maintaining viral suppression in people with HIV who initially had high viral loads.
- Out of 59 participants who started LA-CAB/RPV with detectable viremia, 80% achieved sustained viral suppression after 48 weeks, while overall 92% had viral suppression when considering those who switched treatments.
- The findings suggest that LA-CAB/RPV can significantly aid individuals struggling with adherence to oral HIV medications, highlighting its potential as an effective long-term treatment option.
Background: A multicountry randomized controlled trial has demonstrated that pan-susceptible pulmonary tuberculosis (TB) can be successfully treated with a 4-month regimen of daily isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ). We piloted HPMZ in San Francisco (SF) using a modified version of the US Centers for Disease Control and Prevention HPMZ treatment guidelines.
Methods: In this retrospective cohort, patients consecutively referred to SF TB clinic were evaluated for HPMZ eligibility based on preestablished inclusion/exclusion criteria.
Background: Early evidence suggests long-acting injectable cabotegravir and rilpivirine (LA-CAB/RPV) may be beneficial for people with HIV (PWH) who are unable to attain viral suppression (VS) on oral therapy. Limited guidance exists on implementation strategies for this population.
Setting: Ward 86, a clinic serving publicly insured PWH in San Francisco.
Induction of mycobacterial efflux pumps is a cause of Mycobacterium tuberculosis (Mtb) drug tolerance, a barrier to shortening antitubercular treatment. Verapamil inhibits Mtb efflux pumps that mediate tolerance to rifampin, a cornerstone of tuberculosis (TB) treatment. Verapamil's mycobacterial efflux pump inhibition also limits Mtb growth in macrophages in the absence of antibiotic treatment.
View Article and Find Full Text PDFArticle Synopsis
- - Since May 2022, mpox (monkeypox) has spread to 108 countries, predominantly affecting gay and bisexual men.
- - Two studies conducted in mid-2022 revealed that 8% of men who have sex with men in San Francisco had orthopoxvirus antibodies, while approximately 5.6% of samples from across the U.S. tested positive for monkeypox.
- - The findings suggest that there are likely very few undiagnosed mpox cases in areas with good sexual healthcare access and heightened awareness among patients and healthcare providers.